InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,659.20
(
0.10%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
-1.63%
)
Bitcoin
60,934.90
(
-3.35%
)
Post# of 642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Sokratesaes86

Send PM Follow Ignore
Followers 0
Posts 4
Boards Moderated 0
Alias Born 12/12/2021

Sokratesaes86

Re: None

Sunday, 01/09/2022 10:51:07 AM

Sunday, January 09, 2022 10:51:07 AM

Post# of 642
The results of our exploratory phase 2 study show that C5a inhibition with IFX-1 appears safe in adults with severe COVID-19. Several complement inhibitors are being investigated for COVID-19, the final results of the final study will be published in January 2022, and production is already starting.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent IFRX News
More IFRX News
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!